When mpox infects someone who is pregnant, doctors face a difficult question: is the main treatment safe for both parent and baby? A new surveillance report from the United States offers a very early, cautious glimpse. It describes cases of mpox in cisgender women, including four pregnant people who were treated with the antiviral drug tecovirimat. In those four cases, no adverse reactions to the drug were reported.
This information comes from a simple case series, which is a basic form of medical observation. It didn't compare treated people to untreated ones, and it didn't track patients over time to look for longer-term effects. The report also doesn't tell us anything about how well the drug worked against the mpox infection itself.
Because only four pregnant people were included, this report can't tell us if tecovirimat is truly safe during pregnancy. What it does provide is a small piece of real-world experience that was previously missing. For doctors and patients making urgent decisions, even limited data can be better than no data at all. This isn't a green light — it's a single, cautious data point that researchers will need to build upon with much larger, more rigorous studies.
